Watch LUNG. Know when insiders buy.
One email the day a filing lands. Free.
LUNG
Pulmonx Corp
1.86
+0.02 +1.37%
USD · close Oct 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
57
WATCH · insiders 41, shorts 73
Insiders, 90 days
−$177K
net selling · 0 buys, 14 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $79.7MP/E —DIV YIELD —FCF YIELD -38.50%REV TTM $87.4M −3.4%NET INCOME −$48.1MNET CASH $18.3M52W 1.17 – 2.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $22.8M | −4.6% | 78.0% | −$9.1M | −$10.1M | — | -0.24 | −$5.2M | $1K | −$5.2M | Aug 4 |
| Q1 2026 · Mar 31 | $20.6M | −8.7% | 77.9% | −$13M | −$13.7M | — | -0.33 | −$10.1M | $9K | −$10.1M | Aug 4 |
| Q4 2025 · Dec 31derived | $22.6M | −4.9% | 77.6% | −$9.9M | −$10.4M | — | -0.25 | −$7.1M | $13K | −$7.1M | Mar 10 |
| Q3 2025 · Sep 30 | $21.5M | +5.5% | 74.7% | −$14.4M | −$14M | — | -0.34 | −$8.2M | $89K | −$8.3M | Nov 12 |
| Q2 2025 · Jun 30 | $23.9M | +14.8% | 72.1% | −$14.8M | −$15.2M | — | -0.38 | −$3.9M | $49K | −$4M | Aug 4 |
| Q1 2025 · Mar 31 | $22.5M | +19.5% | 72.5% | −$14.6M | −$14.4M | — | -0.36 | −$13.2M | $301K | −$13.5M | Aug 4 |
| Q4 2024 · Dec 31derived | $23.8M | +23.3% | 74.0% | −$13.4M | −$13.2M | — | -0.33 | −$6.7M | $111K | −$6.8M | Mar 10 |
| Q3 2024 · Sep 30 | $20.4M | +15.4% | 73.7% | −$14.1M | −$14.1M | — | -0.36 | −$7.2M | $416K | −$7.7M | Nov 12 |
| Q2 2024 · Jun 30 | $20.8M | — | 73.7% | −$15.6M | −$15.3M | — | -0.39 | −$5.8M | $469K | −$6.2M | Nov 12 |
| Q1 2024 · Mar 31 | $18.9M | — | 74.7% | −$14.5M | −$13.7M | — | -0.36 | −$11.8M | $451K | −$12.2M | Nov 12 |
| Q4 2023 · Dec 31derived | $19.3M | — | 74.7% | −$13.9M | −$13.9M | — | -0.36 | −$8.4M | $200K | −$8.6M | Feb 25 |
| Q3 2023 · Sep 30 | $17.7M | — | 73.7% | −$15.2M | −$14.9M | — | -0.39 | −$8.6M | $492K | −$9.1M | Nov 1 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $90.5M | 74.2% | −$53.7M | −$54M | -59.7% | -1.33 | −$32.4M | $452K | −$32.8M | — | — |
| FY2024 · to Dec 31 | $83.8M | 74.0% | −$57.7M | −$56.4M | -67.3% | -1.44 | −$31.5M | $1.4M | −$33M | — | — |
| FY2023 · to Dec 31 | $68.7M | 73.9% | −$61.9M | −$60.8M | -88.6% | -1.60 | −$37.6M | $807K | −$38.4M | $0 | — |
| FY2022 · to Dec 31 | $53.7M | 74.3% | −$58.6M | −$58.9M | -109.8% | -1.59 | −$45.1M | $1.3M | −$46.4M | $27K | — |
| FY2021 · to Dec 31 | $48.4M | 73.6% | −$47.3M | −$48.7M | -100.5% | -1.35 | −$41.4M | $3.7M | −$45.1M | $26K | — |
| FY2020 · to Dec 31 | $32.7M | 64.8% | −$32.3M | −$32.2M | -98.5% | -3.16 | −$30.6M | $911K | −$31.5M | $21K | — |
Every number comes from Pulmonx Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.